It's a trade off between what reasonable amount you can get now versus what you think it may be worth 5 or 10 years down the road along with all the execution risks over that timeframe.
NWBO's low on cash position gives it no bargaining power and indirect evidence of that is the failure of NWBO to negotiate reasonable reimbursement rates for the German Sickness Funds for treatments under Hospital Exemption to begin in earnest.
Bear in mind that these bureaucrats aren't even playing either own money but the taxpayers. Imagine how much harder a bargain the Big Pharma executives with drive since they ARE playing with their own money and since compared to the time HE negotiations were going on, NWBO is in FAR worse financial shape.
So at 60b with 450m fully diluted share count would be 133.33$ a share. That would be just crazy for how it currently is valued. I don't personally see it reaching that unless it is FDA approved and they have other standard of care treatments coming out.